FDA confirms benefits of Crestor in more patients

December 11, 2009 8:24:59 AM PST
Federal scientists say AstraZeneca's cholesterol pill Crestor lowers the risk of heart attack, death and stroke in patients without a history of heart disease, though some safety concerns remain. The Food and Drug Administration has confirmed the findings of a AstraZeneca study released last November. The study showed that patients with lower cholesterol and few heart risks could still benefit from taking Crestor, setting the stage for a dramatic expansion in use of the drug.

Now the British drugmaker wants the FDA to broaden Crestor's labeling based on those results.

But the FDA's review also cites several safety concerns, including a higher rate of diabetes in patients taking Crestor.


Load Comments